{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:38:16Z","timestamp":1780583896218,"version":"3.54.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>The purpose of this study was to evaluate the efficacy and safety of low power micro radiofrequency (RF) therapy (\u03bcRFthera<jats:sup>\u00ae<\/jats:sup>) through urethra in the treatment of overactive bladders (OAB) through a prospective, single-blind, placebo-controlled, multi-center clinical protocol.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>One hundred and fourteen patients with refractory OAB were randomized at 2:1 ratio, treatment to control undergoing same procedures except only the micro-RF treatment group at turned \u201con\u201d setting in energy. Bladder diaries recorded during the screening period (3 days before enrollment) and during follow-up period on week 1, 3, and 7, respectively. The patients in control could choose receiving an energized treatment during extension stage.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The treatment efficacy was 76.1%. There was 49.80% rate improvement compared to control (95%CL 32.48%, 67.13%). The crude rate ration (RR) was 2.89, 95% CI (1.67\u20135.01) with <jats:italic>p<\/jats:italic> &amp;lt; 0.001 in uni-variate analysis, while the RR became 2.94, 95% CI (1.67\u20135.16) with <jats:italic>p<\/jats:italic> &amp;lt; 0.001 after adjusted potential confounding factors in multi-variate analysis. Statistically significant improvements have been demonstrated in the frequency of urination, urgency, nocturia, and quality of life (QoL) scores.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Micro RF therapy is safe and effective for the treatment of OAB. The main treatment-related complications were catheterization related complications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trial Registration<\/jats:title><jats:p>Zhejiang Device Registration Certificate No. 202090909, <jats:ext-link>www.chictr.org.cn<\/jats:ext-link>, Clinical Trial Accession Number: ChiCTR2100050096.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.746064","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T09:51:10Z","timestamp":1652349070000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["A Multi-Center, Randomized, Blind, Controlled Clinical Trial of the Safety and Efficacy of Micro Radio Frequency Therapy System for the Treatment of Overactive Bladder"],"prefix":"10.3389","volume":"9","author":[{"given":"Zhi-Hui","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Fei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmeen","family":"Bano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisherjon","family":"Ibrohimov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Fei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Lan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Hong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/nau.1930070502","article-title":"The standardisation of terminology of lower urinary tract function. The international continence society committee on standardisation of terminology Scandinavian","volume":"114","author":"Abrams","year":"1988","journal-title":"J Urol Nephrol Supplementum."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1111\/j.1464-410X.2010.09993.x","article-title":"Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction","volume":"108","author":"Irwin","year":"2011","journal-title":"BJU Int."},{"key":"B3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/nau.22429","article-title":"The prevalence and risk factors of OAB in middle-aged and old people in China","volume":"33","author":"Wen","year":"2014","journal-title":"Neurourol Urodynamics."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study","volume":"50","author":"Irwin","year":"2006","journal-title":"European Urol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/nau.22295","article-title":"The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial\/ethnic group and age: results from OAB-POLL","volume":"32","author":"Coyne","year":"2013","journal-title":"Neurourol Urodyn."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/nau.23513","article-title":"The economic burden of overactive bladder (OAB) and its effects on the costs associated with other chronic, age-related comorbidities in the United States","volume":"37","author":"Durden","year":"2018","journal-title":"Neurourol Urodyn."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1111\/j.1464-410X.2008.07601.x","article-title":"The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study","volume":"101","author":"Coyne","year":"2008","journal-title":"BJU Int."},{"key":"B8","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12894-017-0294-3","article-title":"Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study","volume":"17","author":"Lee","year":"2017","journal-title":"BMC Urol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/JU.0000000000000309","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment 2019","volume":"202","author":"Lightner","year":"2019","journal-title":"J Urol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","article-title":"The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis","volume":"54","author":"Chapple","year":"2008","journal-title":"Eur Urol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1002\/nau.24474","article-title":"Treatment patterns and costs among patients with OAB treated with combination oral therapy, sacral nerve stimulation, percutaneous tibial nerve stimulation, or onabotulinumtoxinA in the United States","volume":"39","author":"Kraus","year":"2020","journal-title":"Neurourol Urodyn."},{"key":"B12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.juro.2017.07.010","article-title":"5-year followup results of a prospective, multicenter study of patients with overactive bladder treated with sacral neuromodulation","volume":"199","author":"Siegel","year":"2018","journal-title":"J Urol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2147\/RRU.S273686","article-title":"Emerging data on the safety and efficacy of transurethral water vapour therapy for benign prostatic hyperplasia","volume":"13","author":"Jones","year":"2021","journal-title":"Res Reports Urol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.pcad.2021.06.005","article-title":"High-power, short-duration ablation for atrial fibrillation: pros and cons","volume":"66","author":"Knotts","year":"2021","journal-title":"Prog Cardiovasc Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"752","DOI":"10.20945\/2359-3997000000411","article-title":"Radiofrequency ablation of thyroid nodules: prospective cost-effectiveness analysis in comparison to conventional thyroidectomy","volume":"65","author":"Schalch","year":"2021","journal-title":"ArcEndocrinol Metabol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.34172\/jlms.2021.56","article-title":"Intravaginal pulsed contractile radiofrequency for stress urinary incontinence treatment; a safety study","volume":"12","author":"Razzaghi","year":"2021","journal-title":"J Lasers Med Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.acuroe.2017.05.003","article-title":"Comparative study of the B-SAQ, OAB-V8 and OAB-V3 questionnaires as screening tools for overactive bladders in clinical practice","volume":"41","author":"Angulo","year":"2017","journal-title":"Actas Urol Esp."},{"key":"B18","first-page":"1252","article-title":"Recommendations for the use of voiding diaries and symptom or quality of life questionnaires in the investigation of non-neurological female urinary incontinence","volume":"17","author":"Le Normand","year":"2007","journal-title":"Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1097\/DCR.0b013e31826c7789","article-title":"Neuromodulation for fecal and urinary incontinence: functional results in 57 consecutive patients from a single institution","volume":"55","author":"Faucheron","year":"2012","journal-title":"Diseases Colon Rectum."},{"key":"B20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41569-020-00451-x","article-title":"Catheter ablation for atrial fibrillation: current indications and evolving technologies","volume":"18","author":"Parameswaran","year":"2021","journal-title":"Nat Rev Cardiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"469","DOI":"10.36076\/ppj.2018.5.469","article-title":"Effectiveness and safety of high-voltage pulsed radiofrequency to treat patients with primary trigeminal neuralgia: a multicenter, randomized, double-blind, controlled study protocol","volume":"21","author":"Jia","year":"2018","journal-title":"Pain Physician."},{"key":"B22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.36076\/ppj.2021.24.89-97","article-title":"The efficacy and safety of the application of pulsed radiofrequency, combined with low-temperature continuous radiofrequency, to the gasserian ganglion for the treatment of primary trigeminal neuralgia: study protocol for a prospective, open-label, parall","volume":"24","author":"Ren","year":"2021","journal-title":"Pain Physician."},{"key":"B23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40122-020-00211-2","article-title":"Basivertebral nerve ablation for the treatment of vertebrogenic pain","volume":"10","author":"Urits","year":"2021","journal-title":"Pain Therapy."},{"key":"B24","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.urology.2019.08.046","article-title":"Initial evaluation of a novel modulated radiofrequency-based bladder denervation device","volume":"134","author":"Okhunov","year":"2019","journal-title":"Urology."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1002\/nau.23183","article-title":"Effects of pulsed-radiofrequency neuromodulation on the rat with overactive bladder","volume":"36","author":"Jen","year":"2017","journal-title":"Neurourol Urodyn."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e5549","DOI":"10.1097\/MD.0000000000005549","article-title":"Pulsed radiofrequency treatment of the superior hypogastric plexus in an interstitial cystitis patient with chronic pain and symptoms refractory to oral and intravesical medications and bladder hydrodistension: a case report","volume":"95","author":"Kim","year":"2016","journal-title":"Medicine."},{"key":"B27","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/nau.23881","article-title":"Initial clinical experience with selective bladder denervation for refractory overactive bladder","volume":"38","author":"Tu","year":"2019","journal-title":"Neurourol Urodyn."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.juro.2009.05.045","article-title":"Rovner Randomized trial of percutaneous tibial nerve stimulation vs. extended-release tolterodine: results from the overactive bladder innovative therapy trial","volume":"182","author":"Peters","year":"2009","journal-title":"Journal Urol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/luts.12136","article-title":"Treatment outcome of overactive bladder patients receiving antimuscarinic therapy for more than 1 year","volume":"10","author":"Hsiao","year":"2018","journal-title":"Low Urin Tract Symptoms."},{"key":"B30","doi-asserted-by":"publisher","first-page":"S216","DOI":"10.1016\/j.juro.2016.10.109","article-title":"OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial","volume":"197","author":"Nitti","year":"2017","journal-title":"J Urol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/nau.22707","article-title":"Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at 12 months in subjects with symptoms of overactive bladder","volume":"35","author":"Noblett","year":"2016","journal-title":"Neurourol Urodyn."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.746064\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T09:51:14Z","timestamp":1652349074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.746064\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":31,"alternative-id":["10.3389\/fmed.2022.746064"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.746064","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,12]]},"article-number":"746064"}}